Evidence map›Paper›PMID 37632363›Full record

ArticleEuropean heart journal2023

Economic burden of cardiovascular diseases in the European Union: a population-based cost study.

Ramon Luengo-Fernandez, Marjan Walli-Attaei, Alastair Gray, Aleksandra Torbica, Aldo P Maggioni, Radu Huculeci, Firoozeh Bairami, Victor Aboyans, Adam D Timmis, Panos Vardas and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06665919 (Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI), which is not on this map. Cited by 174 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06665919 nacompletednot on this map

Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI

TypeinterventionalSponsorVistamedi Ltd.Ran2023 to 2025Enrolled283ConditionsCoronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac EventsArmsCYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Measurement properties of utility-based health-related quality of life measures in cardiac rehabilitation and secondary prevention programs: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ramon Luengo-FernandezHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK.ORCID 0000-0002-2118-2662
Marjan Walli-AttaeiHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK.
Alastair GrayHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK.ORCID 0000-0003-0239-7278
Aleksandra TorbicaCentre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy.ORCID 0000-0001-8938-7608
Aldo P MaggioniANMCO Research Center-Heart Care Foundation, Firenze, Italy.
Radu HuculeciEuropean Society of Cardiology, European Heart Agency, Brussels, Belgium.ORCID 0000-0003-0863-4668
Firoozeh BairamiEuropean Society of Cardiology, European Heart Agency, Brussels, Belgium.
Victor AboyansDepartment of Cardiology, Dupuytren University Hospital, and EpiMaCT, Inserm1098/IRD270, Limoges University, Limoges, France.ORCID 0000-0002-0322-9818
Adam D TimmisWilliam Harvey Research Institute, Queen Mary University London, London, UK.
Panos VardasEuropean Society of Cardiology, European Heart Agency, Brussels, Belgium.ORCID 0000-0002-4499-0806
Jose LealHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK.ORCID 0000-0001-7870-6730

Funding

European Society of Cardiology
6 · The paper itself

Abstract

BACKGROUND AND

aimsCardiovascular disease (CVD) impacts significantly health and social care systems as well as society through premature mortality and disability, with patients requiring care from relatives. Previous pan-European estimates of the economic burden of CVD are now outdated. This study aims to provide novel, up-to-date evidence on the economic burden across the 27 European Union (EU) countries in 2021.

methodsAggregate country-specific resource use data on morbidity, mortality, and health, social and informal care were obtained from international sources, such as the Statistical Office of the European Communities, enhanced by data from the European Society of Cardiology Atlas programme and patient-level data from the Survey of Health, Ageing and Retirement in Europe. Country-specific unit costs were used, with cost estimates reported on a per capita basis, after adjustment for price differentials.

resultsCVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equalling 11% of EU-health expenditure. Productivity losses accounted for 17% (€48 billion), whereas informal care costs were €79 billion (28%). CVD represented a cost of €630 per person, ranging from €381 in Cyprus to €903 in Germany. Coronary heart disease accounted for 27% (€77 billion) and cerebrovascular diseases for 27% (€76 billion) of CVD costs.

conclusionsThis study provides contemporary estimates of the wide-ranging impact of CVD on all aspects of the economy. The data help inform evidence-based policies to reduce the impact of CVD, promoting care access and better health outcomes and economic sustainability.

Indexed as

Cardiovascular DiseasesHealth Care CostsCost of IllnessEuropean UnionFinancial StressHumansCardiovascular diseaseCerebrovascular diseaseCoronary heart diseaseCost

Identifiers

PMID37632363
PMCPMC10691195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.